{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:25:32Z","timestamp":1783441532537,"version":"3.54.6"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,2,9]],"date-time":"2006-02-09T00:00:00Z","timestamp":1139443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> The impact of prolonged subclinical hyperthyroidism on quality of life is unclear. Therefore, we evaluated quality of life in patients with differentiated thyroid carcinoma (DTC) on TSH\u2010suppressive thyroxine therapy as a model for subclinical hyperthyroidism and we investigated whether restoration to euthyroidism affects quality of life.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> We performed a prospective, single\u2010blinded, placebo\u2010controlled, randomized trial of 6\u00a0months\u2019 duration with two parallel groups.<\/jats:p><jats:p><jats:bold>Patients and methods\u2002<\/jats:bold> Twenty\u2010four subjects with a history of differentiated thyroid carcinoma with &gt; 10\u00a0years TSH\u2010suppressive therapy with L\u2010thyroxine completed the study. L\u2010thyroxine dose was replaced by study medication containing L\u2010thyroxine or L\u2010thyroxine plus placebo. Medication was titrated to establish continuation of TSH suppression (low\u2010TSH group) and euthyroidism (euthyroid group). Both groups consisted of 12 patients. We evaluated quality of life using five validated questionnaires.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> At baseline, the somatic disorder questionnaire (SDQ) indicated more somatic dysfunction in patients as compared with reference values, whereas the depression score (HADS) revealed a better score than the reference group. All other quality of life parameters were normal. At baseline, no significant differences between the low\u2010TSH and the euthyroidism groups were observed. After 6\u00a0months, none of the quality of life parameters in the low\u2010TSH group was different from baseline values. In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index\u201020, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7003), although this parameter did not differ from the reference group at baseline. A probable worsening in role limitations as a result of physical problems (Short Form\u201036; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7050) was observed. No improvement in the SDQ score was observed.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> In summary, quality of life in patients with DTC and long\u2010term subclinical hyperthyroidism in general is preserved. Restoration of euthyroidism in general does not affect quality of life.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2006.02458.x","type":"journal-article","created":{"date-parts":[[2006,2,9]],"date-time":"2006-02-09T16:14:33Z","timestamp":1139501673000},"page":"284-291","source":"Crossref","is-referenced-by-count":57,"title":["Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial"],"prefix":"10.1111","volume":"64","author":[{"given":"C. F. A.","family":"Eustatia\u2010Rutten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. P. M.","family":"Corssmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Romijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. A.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,2,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92423-D"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00387.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-18584"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.7.1183"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1990.258.3.E399"},{"key":"e_1_2_5_7_2","first-page":"4701","article-title":"Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle\u2010aged patients","volume":"85","author":"Biondi B.","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1210\/jc.2002-021046","article-title":"The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities","volume":"88","author":"Sgarbi J.A.","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1210\/jcem.87.3.8302","article-title":"Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism","volume":"87","author":"Biondi B.","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc5001.100621"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(00)00263-0"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-110-2-367"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-825925"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.51.311"},{"key":"e_1_2_5_15_2","first-page":"77","article-title":"Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism","volume":"78","author":"Stott D.J.","year":"1991","journal-title":"Quarterly Journal of Medicine"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01667147"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.5.1028"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2592"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100601"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archinte.1988.00380020131018","article-title":"Symptom rating scale for assessing hyperthyroidism","volume":"148","author":"Klein I.","year":"1988","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435982"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.600"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291796004382"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.6.470"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490091"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800521002"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.6.893"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1965.01730060026004"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2006.02458.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2006.02458.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:12:36Z","timestamp":1697227956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2006.02458.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1365-2265.2006.02458.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02458.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,9]]}}}